BMJ Oncology adheres to the highest standards concerning its editorial policies on publication ethics, scientific misconduct, consent and peer review criteria. The journal follows guidance produced by bodies that include the Committee on Publication Ethics (COPE), the World Association of Medical Editors (WAME) and the International Committee of Medical Journal Editors (ICMJE). To view all BMJ Journal policies, please refer to the BMJ Author Hub policies page, including information about our Editors' roles and responsibilities. Authors are required to submit a statement that their study obtained ethics approval (or a statement that it was not required and why) and that participants gave informed consent. Editors will consider whether the work is morally acceptable as determined by the World Medical Association’s Declaration of Helsinki. In addition to this, in line with General Medical Council guidelines, an article that contains personal medical information about an identifiable living individual requires patients’ explicit consent (in the format of a signed BMJ patient consent form) before we will publish it. Please find further details on BMJ research ethics policies (human participants and animals) and consent for publication, including a link to the downloadable consent form.To make the best decision on how to deal with a manuscript, BMJ Oncology needs to know about any competing interests authors may have; this includes any commercial, financial or non financial associations that may be relevant to the submitted article. Authors must download and complete a copy of the ICMJE Disclosure of Interest form. In addition to this BMJ Oncology ensures that all advertising and sponsorship associated with the journal does not influence editorial decisions, is immediately distinguishable from editorial content and meets all other BMJ guidelines. Please find more information about competing interests.
We take seriously all possible cases of misconduct. If an Editor, author or reader has concerns that a submitted article contains something that might be considered to constitute misconduct in research, publication or professional behaviour they should forward their concerns to the journal. The publisher will deal with allegations appropriately following ICMJE and COPE guidelines. Corrections and retractions are considered where an article has already been published; corrections, expressions of concern or a retraction notice will be published as soon as possible in line with the BMJ correction and retraction policy.
As an open access journal, BMJ Oncology adheres to the Budapest Open Access Initiative definition of open access. Articles are published under an exclusive licence or non-exclusive licence for UK Crown employees or where BMJ has agreed CC BY applies. For US Federal Government officers or employees acting as part of their official duties, the terms are as stated in accordance with our licence terms. Authors or their employers retain copyright. Such open access articles can be reused under the terms of the relevant Creative Commons licence to facilitate reuse of the content. Please refer to the BMJ Oncology Author Licence. More information on copyright and authors’ rights. When publishing in BMJ Oncology, authors choose between two licence types – CC BY-NC and CC BY (both require payment of an article processing charge).
As an author you may post your article in an institutional or subject repository, or on a scientific social sharing network. You may also link your published article to your preprint (if applicable). What you can do with your article, without seeking permission, depends on the licence you have chosen and the version of your article. Please refer to the BMJ author self-archiving and permissions policies page for more information.
Preprints foster openness, accessibility and collaboration by allowing authors to make their findings immediately available to the research community and receive feedback on an article before it is submitted to a journal for formal publication.
BMJ fully supports and encourages the archiving of preprints in any recognised, not-for-profit server such as medRxiv. BMJ does not consider the posting of an article in a dedicated preprint repository to be prior publication.
BMJ Oncology is an open access journal and levies an article processing charge (APC) of 2,060 GBP (excluding VAT for UK and EU authors). There are no submission, colour or page charges. As a thank you to our peer reviewers, authors who have reviewed for the journal are entitled to 25% off the APC if they submit to BMJ Oncology within a year of completing their review.
BMJ Oncology offers waivers of the full Article Processing Charge (100% discount) where all authors on a paper are based in low-income countries. See full waiver list*. Requests for waivers should be made before or during initial submission**. If an article reports funding from a funder with an open access mandate or policy that covers paying APCs, BMJ expects that the APC will be paid. Visit our author hub to learn more about our waivers policy and how to request one. You might be eligible for institutional funding. A number of institutions have open access agreements with BMJ which can either cover the whole cost of open access publishing for authors at participating institutions or can allow authors to receive a discount of the Article Processing Charge (APC). Visit BMJ’s open access agreements page to find out whether your institution is a member and what discounts you may be entitled to. *This list is based on the HINARI Core Offer Groups A and B, and the World Bank Country and Lending Groups. It is updated annually. **Please note that applications for waivers or discounts should be made during initial submission and not after an article has been accepted. Editors are not involved in this process and the ability to pay has no bearing on editorial decisions. Payment will not be required unless your article is accepted. Accepted articles will not be published until payment has been received. BMJ does not refund APCs once paid.
BMJ Oncology submissions are predominantly unsolicited and all articles submitted are subject to peer review. The journal operates single anonymised peer review whereby the names of the reviewers are hidden from the author; usually two external reviewer reports are obtained before an Original research or Review article is accepted for publication. Articles authored by a member of a journal’s editorial team are independently peer reviewed; an editor will have no input or influence on the peer review process or publication decision for their own article. For more information on what to expect during the peer review process please refer to BMJ Author Hub - the peer review process. BMJ is committed to transparency. Every article we publish includes a description of its provenance (commissioned or not commissioned) and whether it was internally or externally peer reviewed.
BMJ requests that all reviewers adhere to a set of basic principles and standards during the peer review process; these are based on the COPE Ethical Guidelines for Peer Reviewers. Please refer to our peer review terms and conditions.Plagiarism is the appropriation of the language, ideas or thoughts of another without crediting their true source and representation of them as one’s own original work. BMJ is a member of CrossCheck by CrossRef and iThenticate. iThenticate is a plagiarism screening service that verifies the originality of content submitted before publication. BMJ runs manuscripts through iThenticate during the peer review process. Authors, researchers and freelancers can also use iThenticate to screen their work before submission by visiting www.ithenticate.com. Reader responses, questions and comments to published content are welcomed by BMJ Oncology; these should be submitted electronically through the journal’s website. Please find further details on how to publish a response and the terms and conditions.
BMJ is committed to ensuring that all good quality research is published. Our article transfer service helps authors find the best journal for their research while providing an easy and smooth publication process. As part of this service, once authors agree to transfer their manuscript all versions, supplementary files and peer reviewer comments are automatically transferred, without the need to resubmit or reformat.
Authors who submit oncology papers to other BMJ journals and whose work is rejected on the grounds of priority will be offered the option of transferring to BMJ Oncology.Please note that the article transfer service does not guarantee acceptance but you should receive a quicker initial decision on your manuscript. Contact the Article Transfer Service team at firstname.lastname@example.org.
BMJ Oncology mandates ORCID iDs for the submitting author at the time of article submission; co-authors and reviewers are strongly encouraged to connect their ScholarOne accounts to ORCID. We believe that the increased use and integration of ORCID iDs will be beneficial for the whole research community. Find more information about ORCID and BMJ’s policy on our Author Hub.
BMJ Oncology adheres to BMJ's Tier 2 data policy. We strongly encourage that data generated by your research that supports your article be made available as soon as possible, wherever legally and ethically possible. We also require data from clinical trials to be made available upon reasonable request. To adhere to ICMJE guidelines, we require that a data sharing plan must be included with trial registration for clinical trials that begin enrolling participants on or after 1st January 2019. Changes to the plan must be noted in the Data Availability Statement and updated in the registry record. All research articles must contain a Data Availability Statement. For more information and FAQs, please see BMJ's Data Sharing Policy page.The DataCite organisation has a growing list of other repositories for research data. Authors that agree to share their data are eligible for a 25% discount on the Article Processing Charge.
BMJ encourages active patient and public involvement in clinical research as part of its patient and public partnership strategy. To support co-production of research we request that authors provide a Patient and Public Involvement statement in the methods section of their papers, under the subheading ‘Patient and public involvement’. We appreciate that patient and public involvement is relatively new and may not be feasible or appropriate for all papers. We therefore continue to consider papers where patients were not involved.
The Patient and Public Involvement statement should provide a brief response to the following questions, tailored as appropriate for the study design reported (please find example statements here):
- At what stage in the research process were patients/the public first involved in the research and how?
- How were the research question(s) and outcome measures developed and informed by their priorities, experience, and preferences?
- How were patients/the public involved in the design of this study?
- How were they involved in the recruitment to and conduct of the study?
- Were they asked to assess the burden of the intervention and time required to participate in the research?
- How were (or will) they be involved in your plans to disseminate the study results to participants and relevant wider patient communities (e.g. by choosing what information/results to share, when, and in what format)?
A rapid response is a moderated but not peer reviewed online response to a published article in BMJ Oncology; it will not receive a DOI and will not be indexed. Find out more about how to submit a response.
Please review the below article type specifications including the required article lengths, illustrations, table limits and reference counts. The word count excludes the title page, abstract, tables, acknowledgements, contributions and references. Manuscripts should be as succinct as possible. For further support when making your submission please refer to the resources available on the BMJ Author Hub. Here you will find information on writing and formatting your research through to the peer review process and promoting your paper. We encourage authors to ensure that research articles are written in accordance with the relevant research reporting guideline; for the reporting and analysis of refractive data please adhere to the guidelines available here. You may also wish to use the language editing and translation services provided by BMJ Author Services.
- Original research
Original research manuscripts should include the following:
- Title - include the research question and the study design
- Keywords - up to four
- Structured Abstract - include the following headings “Objective”, “Methods and Analysis”, “Results” and “Conclusion”
- Materials and Methods
Abstract Style/Limit: Structured; 250 words Word Limit: 4,000 Figure/Table Limit: 5 Reference Limit: 100 Please include the key messages of your article after your abstract using the following headings. This section should be no more than 3-5 sentences and should be distinct from the abstract; be succinct, specific and accurate.
- What is already known on this topic - summarise the state of scientific knowledge on this subject before you did your study and why this study needed to be done
- What this study adds - summarise what we now know as a result of this study that we did not know before
- How this study might affect research, practice or policy - summarise the implications of this study
These are mainly commissioned by the Editor; authors who wish to submit an unsolicited review should contact the Editorial Office to discuss their proposal before submission
Abstract Style/Limit: Unstructured; 250 words Word Limit: 4,000 Figure/Table Limit: 5 References: 100
Editorials are usually commissioned. We don’t accept unsolicited editorials via Scholar One but you are welcome to pitch us your idea for an editorial by emailing Kstewart@bmj.com. A member of the editorial team will get in touch to let you know if we wish to encourage submission of the full article. Editorials are usually responses to a topical issue. They must be evidence-based, but journalistic in style and written with an international general oncology audience in mind. We particularly value pitches authored or co-authored by patient advocates, representatives, and leaders. All authors must declare their interests on this form and have them approved before we encourage a full submission.
Abstract Style/Limit: none Word Limit: 800 Figure/Table Limit: 2 Reference limit:: 12
BMJ Publishing Group journals are willing to consider publishing supplements to regular issues. Supplement proposals may be made at the request of:
- The journal editor, an editorial board member or a learned society may wish to organise a meeting, sponsorship may be sought and the proceedings published as a supplement.
- The journal editor, editorial board member or learned society may wish to commission a supplement on a particular theme or topic. Again, sponsorship may be sought.
- BMJ Oncology itself may have proposals for supplements where sponsorship may be necessary.
- A sponsoring organisation, often a pharmaceutical company or a charitable foundation, that wishes to arrange a meeting, the proceedings of which will be published as a supplement. In all cases, it is vital that the journal's integrity, independence and academic reputation is not compromised in any way.
When contacting us regarding a potential supplement, please include as much of the information below as possible.
- Journal in which you would like the supplement published
- Title of supplement and/or meeting on which it is based
- Date of meeting on which it is based
- Proposed table of contents with provisional article titles and proposed authors
- An indication of whether authors have agreed to participate
- Sponsor information including any relevant deadlines
- An indication of the expected length of each paper Guest Editor proposals if appropriate